These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 1988362

  • 1. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
    Yedema KA, Kenemans P, Wobbes T, van Kamp GJ, de Bruijn HW, Thomas CM, Massuger LF, Schijf CP, Bon GG, Vermorken JB.
    Int J Cancer; 1991 Jan 21; 47(2):170-9. PubMed ID: 1988362
    [Abstract] [Full Text] [Related]

  • 2. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
    Eskelinen M, Tikanoja S, Brown J.
    Anticancer Res; 1990 Jan 21; 10(4):959-62. PubMed ID: 2382995
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients.
    Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Schwartz DC.
    Tumour Biol; 1991 Jan 21; 12(2):82-90. PubMed ID: 2028182
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
    Nicolini A, Ferdeghini M, Colombini C, Carpi A.
    J Nucl Med Allied Sci; 1990 Jan 21; 34(4):309-13. PubMed ID: 2090796
    [Abstract] [Full Text] [Related]

  • 5. Correlation between changes in the tumour markers CA-M26 and CA-M29 and standard response evaluation in patients with metastatic breast cancer.
    van der Gaast A, Hulshof C, Kok TC, van Loon E, Splinter TA.
    Eur J Cancer; 1993 Jan 21; 29A(6):870-3. PubMed ID: 8484981
    [Abstract] [Full Text] [Related]

  • 6. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas.
    Yedema CA, Kenemans P, Wobbes T, Thomas CM, Bon GG, Mulder C, Voorhorst FJ, Verstraeten AA, van Kamp GJ, Hilgers J.
    Tumour Biol; 1992 Jan 21; 13(1-2):18-26. PubMed ID: 1589694
    [Abstract] [Full Text] [Related]

  • 7. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values.
    Bon GG, Kenemans P, Verstraeten R, van Kamp GJ, Hilgers J.
    Am J Obstet Gynecol; 1996 Jan 21; 174(1 Pt 1):107-14. PubMed ID: 8571992
    [Abstract] [Full Text] [Related]

  • 8. CA 549 as a marker in breast cancer.
    Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Dorsa R, Schwartz DC.
    Int J Biol Markers; 1991 Jan 21; 6(3):139-43. PubMed ID: 1791307
    [Abstract] [Full Text] [Related]

  • 9. Serum levels of squamous cell carcinoma antigen and ovarian carcinoma antigen (CA 125) in patients with benign and malignant diseases of the uterine cervix.
    Gocze PM, Vahrson HW, Freeman DA.
    Oncology; 1994 Jan 21; 51(5):430-4. PubMed ID: 8052484
    [Abstract] [Full Text] [Related]

  • 10. Monoclonal antibodies reactive with mucin glycoproteins found in sera from breast cancer patients.
    Linsley PS, Brown JP, Magnani JL, Horn D.
    Cancer Res; 1988 Apr 15; 48(8):2138-48. PubMed ID: 2450646
    [Abstract] [Full Text] [Related]

  • 11. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients.
    Devine PL, McGuckin MA, Ramm LE, Ward BG, Pee D, Long S.
    Cancer; 1993 Sep 15; 72(6):2007-15. PubMed ID: 7689923
    [Abstract] [Full Text] [Related]

  • 12. Mucin-like carcinoma-associated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon.
    Bon GG, Verheijen RH, Zuetenhorst JM, van Kamp GJ, Verstraeten AA, Kenemans P.
    Gynecol Obstet Invest; 1996 Sep 15; 42(1):58-62. PubMed ID: 8840180
    [Abstract] [Full Text] [Related]

  • 13. Tumor antigen NB/70K and CA 125 levels in the blood of preoperative ovarian cancer patients and controls: a preliminary report of the use of the NB12123 and CA 125 radioimmunoassays alone and in combination.
    Knauf S, Bast RC.
    Int J Biol Markers; 1988 Sep 15; 3(2):75-81. PubMed ID: 3243980
    [Abstract] [Full Text] [Related]

  • 14. [Clinical usefulness of CA M26 and CA M29 in breast carcinoma].
    Quaranta M, Micelli G, Coviello M, Donadeo A, Lozupone A, Schittulli F.
    J Nucl Med Allied Sci; 1990 Sep 15; 34(4 Suppl):35-8. PubMed ID: 2092146
    [No Abstract] [Full Text] [Related]

  • 15. The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix.
    de Bruijn HW, Duk JM, van der Zee AG, Pras E, Willemse PH, Boonstra H, Hollema H, Mourits MJ, de Vries EG, Aalders JG.
    Tumour Biol; 1998 Sep 15; 19(6):505-16. PubMed ID: 9817980
    [Abstract] [Full Text] [Related]

  • 16. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
    Suzuki H, Teshima K, Noda K.
    Gan To Kagaku Ryoho; 1984 Dec 15; 11(12 Pt 2):2719-23. PubMed ID: 6594978
    [Abstract] [Full Text] [Related]

  • 17. Experiences with SCC antigen, a new tumor marker for cervical carcinoma.
    Meier W, Eiermann W, Stieber P, Schneider A, Fateh-Moghadam A, Hepp H.
    Eur J Cancer Clin Oncol; 1989 Nov 15; 25(11):1555-9. PubMed ID: 2591447
    [Abstract] [Full Text] [Related]

  • 18. Tumor markers and oncogene expression in thyroid cancer using biochemical and immunohistochemical studies.
    Hashimoto T, Matsubara F, Mizukami Y, Miyazaki I, Michigishi T, Yanaihara N.
    Endocrinol Jpn; 1990 Apr 15; 37(2):247-54. PubMed ID: 1699752
    [Abstract] [Full Text] [Related]

  • 19. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
    Xu FJ, Yu YH, Daly L, DeSombre K, Anselmino L, Hass GM, Berchuck A, Soper JT, Clarke-Pearson DL, Boyer C.
    J Clin Oncol; 1993 Aug 15; 11(8):1506-10. PubMed ID: 8336189
    [Abstract] [Full Text] [Related]

  • 20. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
    Kobayashi H, Terao T, Kawashima Y.
    J Clin Oncol; 1991 Jun 15; 9(6):983-7. PubMed ID: 1851822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.